Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
PLoS Medicine,
Notice of republication This article was republished on October 20, 2020, to remove a Supporting Information file that was…